Immuneering Corp (IMRX)

Currency in USD
4.100
-0.120(-2.84%)
Closed·
After Hours
4.160+0.060(+1.46%)
·
IMRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week High
Fair Value
Day's Range
4.0804.689
52 wk Range
1.0004.689
Key Statistics
Prev. Close
4.22
Open
4.28
Day's Range
4.08-4.689
52 wk Range
1-4.689
Volume
979.09K
Average Volume (3m)
1.24M
1-Year Change
244.54%
Book Value / Share
1.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.250
Upside
+174.39%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Immuneering Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Immuneering Corp Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Compare IMRX to Peers and Sector

Metrics to compare
IMRX
Peers
Sector
Relationship
P/E Ratio
−2.4x−2.0x−0.5x
PEG Ratio
0.45−0.040.00
Price/Book
3.5x0.8x2.6x
Price / LTM Sales
-87.7x3.2x
Upside (Analyst Target)
160.7%261.7%41.9%
Fair Value Upside
Unlock18.7%4.3%Unlock

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.250
(+174.39% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-0.44 / -0.49
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMRX Income Statement

People Also Watch

9.320
HYPD
-19.10%
39.50
BMNR
-2.06%
2.29
BMGL
+4.09%
7.930
BBAI
+7.60%

FAQ

What Stock Exchange Does Immuneering Trade On?

Immuneering is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Immuneering?

The stock symbol for Immuneering is "IMRX."

What Is the Immuneering Market Cap?

As of today, Immuneering market cap is 147.54M.

What Is Immuneering's Earnings Per Share (TTM)?

The Immuneering EPS (TTM) is -1.96.

When Is the Next Immuneering Earnings Date?

Immuneering will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is IMRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Immuneering Stock Split?

Immuneering has split 0 times.

How Many Employees Does Immuneering Have?

Immuneering has 54 employees.

What is the current trading status of Immuneering (IMRX)?

As of 24 Jul 2025, Immuneering (IMRX) is trading at a price of 4.10, with a previous close of 4.22. The stock has fluctuated within a day range of 4.08 to 4.69, while its 52-week range spans from 1.00 to 4.69.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.